Víctor H. Jiménez‐Zepeda

Author

Also Known As

Jimenez-Zepeda, Victor H., V H Jimenez-Zepeda, V H Jiménez-Zepeda, V Jimenez-Zepeda, V. H. JIMENEZ‐ZEPEDA, V. Jimenez-Zepeda, V.H. Jimenez-Zepeda, Victor H. Jimenez-Zepeda, Victor H Jimenez Zepeda, Victor H Jimenez-Zepeda

162

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of Calgary Princess Margaret Cancer Centre Mayo Clinic in Arizona Alberta Health Services Calgary Laboratory Services

About

Víctor H. Jiménez‐Zepeda is an author at University of Calgary specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	737
2	Health Sciences	12	12	346
3	Blood Transplantation	4	4	105
4	Cell Biology	4	4	90
5	Public Health	1	1	27

Víctor H. Jiménez‐Zepeda

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis Joseph Mıkhael, Steven R. Schuster, Víctor H. Jiménez‐Zepeda, Blood	2012	373
Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia Esteban Braggio, Jonathan J. Keats, Xavier Leleu, Cancer Research	2009	148
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Víctor H. Jiménez‐Zepeda, Joseph Mıkhael, Andrew Winter, Biology of Blood and Marrow Transplantation Progressive Multiple MyelomaCell TherapyImmunologyOverall SurvivalSalvage Therapy	2011	115
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents Christine I. Chen, Esther Masih‐Khan, Haiyan Jiang, British Journal of Haematology	2013	114
Leukocyte cell-derived chemotaxin 2 (LECT2)–associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States Oana Madalina Mereuta, Jason D. Theis, Julie A. Vrana, Blood	2014	87
Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy Noémie Leblay, Ranjan Maity, Elie Barakat, Blood	2020	70
Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis Erin Karlstedt, Víctor H. Jiménez‐Zepeda, Jonathan G. Howlett, Journal of Cardiac Failure MedicineUrsodeoxycholic AcidPharmacologyTransthyretin Cardiac AmyloidosisClinical Experience	2019	62
Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents Víctor H. Jiménez‐Zepeda, Donna Reece, Suzanne Trudel, Bone Marrow Transplantation Hematological MalignancyRadiation OncologyMedicineImmunologyPathology	2014	57
Plasma cell leukemia: a rare condition Víctor H. Jiménez‐Zepeda, Virginia Domínguez Annals of Hematology Hematological MalignancyMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyHistopathology	2006	50
Revised International Staging System Applied to Real World Multiple Myeloma Patients Víctor H. Jiménez‐Zepeda, Peter Duggan, Paola Neri, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2016	41

Page 1